Specialty Pharmaceuticals Businesses for Sale and Investment

We are working with five clients. We are a research-based product development partner to pharmaceutical companies. Promoter experience: Promoter is a pharmaceutical professional with 18+ years of work experience (Formulation scientist) turned to healthcare entrepreneur. In 3 years, business will reach USD 2 million revenue per year. We signed up new clients this year and have already achieved INR 1 Cr for this year. More clients are in the pipeline. We generate almost equal revenue from fee for service model and in-house asset sale model.

Ahmedabad based pharmaceutical research company focusing on the NDA, 505 (B) (2), and complex formulations. - We have 8 products in the pipeline for 505 (2) (2) US along with a ready contract R&D business of $1 million. - Business has no liability. - Company has 2 shareholders. - We have 4 active US clients who give regular business. - We have confirmed orders for the future which will be forwarded to the new buyer.

Ahmedabad based pharmaceutical research company focusing on the NDA, 505 (B) (2), and complex formulations. - We have 8 products in the pipeline for 505 (2) (2) US along with a ready contract R&D business of $1 million. - Business has no liability. - Company has 2 shareholders. - We have 4 active US clients who give regular business. - We have confirmed orders for the future which will be forwarded to the new buyer.

We are a pharma company established in Nepal and have a pharma wholesale unit. - The business has tie-ups with many wholesale and retail outlet. - Pharmaceutical industry in Nepal has been emerging as the best investment sector in the last few years. - We are planning to start our own manufacturing unit. The unit is not operational as of now. - The building and some machinery are ready. - We specialize in allopathic medicines. - Have more than 15 years of experience in this sector.

Updates on the business: The facility will have growing/extraction/distillation/packaging and R&D lab facilities in order to follow the entire stage of production from mother plants to crystallized forms of stand-alone cannabinoids. The intended R&D lab will be almost 200 sq. m. and will allow us to study lesser-known cannabinoids, and after the start of construction, we are going to sign the 'Partnership Joint Research' program with Athens University. Currently have signed a partnership agreement with a running pharmaceutical company on product supply + joint research program. Later on, we will focus on the distribution channels in each country of presence in order to be prepared to scale to the B2C market with potential own generic medicine and potentially edibles, but that will be decided by the market needs and legislation. We have received an installation license for such end products and as the project progresses we will add new products to the list: - Dried hemp flower > 0.2% THC in the form of teabag (tea bag) for oral consumption; - Hemp oil in drops for oral consumption > 0.2% THC; - Hemp oil for sublingual oral consumption (spray) > 0.2% THC; - Soft cannabis capsules for oral consumption > 0.2% THC; - Capsules with dried hemp blossom > 0.2% THC in powder form for oral consumption. At the moment we have: License and permits; Architectural and engineering plans; Purchase offers from equipment suppliers; All described production processes and laboratories; Long-term land lease for 30+ years with first an option of first to purchase it; Long-term lease and right of build on the neighboring land for the second stage of construction; The entire legal structure of the holding; Verification of processes and architectural solutions under EU GACP & EU GMP standards. By the end of last year have applied for the state subsidy of EUR 3.5mil and have the option to apply for the second state subsidy next year. Additionally, the project has a right for setting fixed corporate tax for the next 12 years. Overall the production facility is projected to grow 6.5+ tons of dried biomaterial (running at 70% capacity) on a single-tier growing table with the ability of scale and potential purchase of third-party biomaterial certified by GACP standards. The EU GMP Laboratory is projected to produce 2+ tons of fine oil with an option of scaling by putting a second processing line. Additionally, the project is built in mind with an option for a second-stage expansion through the building of an additional production site on the neighboring land.

Our company developing and market potential pharmaceutical medicines that have no side effects. - The business has invested heavily in the research and development of anti-viral drugs. - Today, we have finished R&D and are ready to start production of a new drug that can help to prevent and treat many diseases including COVID-19. - The investment will be utilized to commence production and fulfil purchase orders from around the world.